Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancerMichael A Carducci, Luna Musib, Merrill S Kies, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastomaWolfgang Wick, Vinay K Puduvalli, Marc C Chamberlain, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 4, 2024
Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy SubjectsSmita Kshirsagar, Ya-Chi Chen, Jiajie Yu, et al.The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.Targeted Oncology|June 17, 2022
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II StudyTanya Trippett, Helen Toledano, Quentin Campbell Hewson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancerJeany M Rademaker-Lakhai, Laurens V Beerepoot, Niven Mehra, et al.Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.Cancer Research|August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenograftsJeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.Cancer Discovery|November 23, 2016
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid TumorsCristina Saura, Desamparados Roda, Susana Roselló, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2007
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphomaMichael J Robertson, Brad S Kahl, Julie M Vose, et al.Pageof 5